Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lumateperone (Primary) ; Antidepressants
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms Study 502
  • Sponsors Intra-Cellular Therapies

    • Most Recent Events

    • 03 Dec 2024 According to an Intra-Cellular Therapies media release, the company announced that it has recently submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for CAPLYTA (lumateperone) for the treatment of Major Depressive Disorder (MDD) in adults, as adjunctive therapy to antidepressants. The submission is on the basis of Study 501 and Study 502.
    • 07 Nov 2024 Results published in the Intra-Cellular Media Release.
    • 07 Nov 2024 According to an Intra-Cellular Therapies media release, result from this trial was presented at Psych Congress held October 29- November 2 in Boston and Neuroscience Education Institute (NEI) Congress being held November 7-10 in Colorado Springs.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top